Circ Cardiovasc Intervent -- Table of Contents (1 [3])

Volume 1, Issue 3; December, 2008

Editorials
Original Articles
Controversies in Interventional Cardiology
Images and Case Reports in Interventional Cardiology
Author Index

To see an article, click its "Full Text" or "PDF" link. To review many abstracts, check the boxes to the left of the titles you want, and click the "Get All Checked Abstract(s)" button. To see one abstract at a time, click its "Abstract" link.

button_lock_image article is free immediately upon publication

	Editorials
	Transcatheter Aortic Valve Implantation: Past, Present, and Future Howard C. Herrmann Circ Cardiovasc Intervent. 2008;1:159-160, doi:10.1161/CIRCINTERVENTIONS.108.833533 Extract \| Full Text \| PDF
	Drug-Eluting or Bare-Metal Stents for ST Elevation Myocardial Infarction Can Observational Data Balance the Risk Benefit Equation? Donald E. Cutlip Circ Cardiovasc Intervent. 2008;1:161-163, doi:10.1161/CIRCINTERVENTIONS.108.834036 Extract \| Full Text \| PDF
	Change We Can Believe In: The Hyper-Evolution of Percutaneous Coronary Intervention for Unprotected Left Main Disease With Drug-Eluting Stents Matthew J. Price, David E. Kandzari, and Paul S. Teirstein Circ Cardiovasc Intervent. 2008;1:164-166, doi:10.1161/CIRCINTERVENTIONS.108.832477 Extract \| Full Text \| PDF
	Original Articles
	Progress and Current Status of Percutaneous Aortic Valve Replacement: Results of Three Device Generations of the CoreValve Revalving System Eberhard Grube, Lutz Buellesfeld, Ralf Mueller, Barthel Sauren, Bernfried Zickmann, Dinesh Nair, Harald Beucher, Thomas Felderhoff, Stein Iversen, and Ulrich Gerckens Circ Cardiovasc Intervent. 2008;1:167-175, doi:10.1161/CIRCINTERVENTIONS.108.819839 Abstract \| Full Text \| PDF
	Clinical Outcome After Primary Percutaneous Coronary Intervention With Drug-Eluting and Bare Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction Lisette Okkels Jensen, Michael Maeng, Per Thayssen, Anne Kaltoft, Hans Henrik Tilsted, Morten Bøttcher, Jens Flensted Lassen, Knud Nørregaard Hansen, Lars Romer Krusell, Klaus Rasmussen, Knud Erik Pedersen, Lars Pedersen, Søren Paaske Johnsen, Henrik Toft Sørensen, and Leif Thuesen Circ Cardiovasc Intervent. 2008;1:176-184, doi:10.1161/CIRCINTERVENTIONS.108.794578 Abstract \| Full Text \| PDF
	Impact of Bifurcation Technique on 2-Year Clinical Outcomes in 773 Patients With Distal Unprotected Left Main Coronary Artery Stenosis Treated With Drug-Eluting Stents Tullio Palmerini, Antonio Marzocchi, Corrado Tamburino, Imad Sheiban, Massimo Margheri, Giuseppe Vecchi, Giuseppe Sangiorgi, Andrea Santarelli, Antonio Bartorelli, Carlo Briguori, Luigi Vignali, Francesco Di Pede, Angelo Ramondo, Luigi Inglese, Marco De Carlo, Giovanni Falsini, Alberto Benassi, Cataldo Palmieri, Vincenzo Filippone, Diego Sangiorgi, Fabio Barlocco, and Stefano De Servi Circ Cardiovasc Intervent. 2008;1:185-192, doi:10.1161/CIRCINTERVENTIONS.108.800631 Abstract \| Full Text \| PDF \| Clinical Perspective
	Interference of Drug-Eluting Stents With Endothelium-Dependent Coronary Vasomotion: Evidence for Device-Specific Responses Michalis Hamilos, Jaydeep Sarma, Miodrag Ostojic, Thomas Cuisset, Giovanna Sarno, Narbeh Melikian, Argyrios Ntalianis, Olivier Muller, Emanuele Barbato, Branco Beleslin, Dragan Sagic, Bernard De Bruyne, Jozef Bartunek, and William Wijns Circ Cardiovasc Intervent. 2008;1:193-200, doi:10.1161/CIRCINTERVENTIONS.108.797928 Abstract \| Full Text \| PDF \| Clinical Perspective
	Poor 1-Year Outcomes After Percutaneous Coronary Interventions in Systemic Lupus Erythematosus: Report From the National Heart, Lung, and Blood Institute Dynamic Registry Kathleen Maksimowicz-McKinnon, Faith Selzer, Susan Manzi, Kevin E. Kip, Suresh R. Mulukutla, Oscar C. Marroquin, Thomas C. Smitherman, Lewis H. Kuller, David O. Williams, and Mary Chester M. Wasko Circ Cardiovasc Intervent. 2008;1:201-208, doi:10.1161/CIRCINTERVENTIONS.108.788745 Abstract \| Full Text \| PDF
	Inhibition of Apoptosis Through Localized Delivery of Rapamycin-Loaded Nanoparticles Prevented Neointimal Hyperplasia and Reendothelialized Injured Artery Maram K. Reddy, Jaspreet K. Vasir, Sanjeeb K. Sahoo, Tapan K. Jain, Murali M. Yallapu, and Vinod Labhasetwar Circ Cardiovasc Intervent. 2008;1:209-216, doi:10.1161/CIRCINTERVENTIONS.108.830018 Abstract \| Full Text \| PDF \| Clinical Perspective
	Controversies in Interventional Cardiology
	Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Be Continued for More Than One Year and Preferably Indefinitely Adnan K. Chhatriwalla and Deepak L. Bhatt Circ Cardiovasc Intervent. 2008;1:217-225, doi:10.1161/CIRCINTERVENTIONS.108.811380 Extract \| Full Text \| PDF \| Response
	Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Not Be Continued for More Than 1 Year and Preferably Indefinitely Antonio Colombo and Robert T. Gerber Circ Cardiovasc Intervent. 2008;1:226-232, doi:10.1161/CIRCINTERVENTIONS.108.810853 Extract \| Full Text \| PDF \| Response
	Images and Case Reports in Interventional Cardiology
	Apical Aortic Valve Implantation in a Patient With a Mechanical Valve Prosthesis in Mitral Position Josep Rodés-Cabau, Eric Dumont, Santiago Miró, Daniel Doyle, Robert De Larochellière, Marie-Annick Clavel, Jacques Villeneuve, Sebastien Bergeron, Mario Senechal, and Philippe Pibarot Circ Cardiovasc Intervent. 2008;1:233, doi:10.1161/CIRCINTERVENTIONS.108.813592 Extract \| Full Text \| PDF \| Data Supplement
	Author Index
	Volume 1, August–December, 2008 Circ Cardiovasc Intervent. 2008;1:236, doi:10.1161/CIRCINTERVENTIONS.108.201001 Extract \| Full Text \| PDF

Spotlight

TOC Spotlight File

Volume 1, Issue 3; December, 2008

Editorials

Transcatheter Aortic Valve Implantation: Past, Present, and Future

Drug-Eluting or Bare-Metal Stents for ST Elevation Myocardial Infarction Can Observational Data Balance the Risk Benefit Equation?

Change We Can Believe In: The Hyper-Evolution of Percutaneous Coronary Intervention for Unprotected Left Main Disease With Drug-Eluting Stents

Original Articles

Progress and Current Status of Percutaneous Aortic Valve Replacement: Results of Three Device Generations of the CoreValve Revalving System

Clinical Outcome After Primary Percutaneous Coronary Intervention With Drug-Eluting and Bare Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction

Impact of Bifurcation Technique on 2-Year Clinical Outcomes in 773 Patients With Distal Unprotected Left Main Coronary Artery Stenosis Treated With Drug-Eluting Stents

Interference of Drug-Eluting Stents With Endothelium-Dependent Coronary Vasomotion: Evidence for Device-Specific Responses

Poor 1-Year Outcomes After Percutaneous Coronary Interventions in Systemic Lupus Erythematosus: Report From the National Heart, Lung, and Blood Institute Dynamic Registry

Inhibition of Apoptosis Through Localized Delivery of Rapamycin-Loaded Nanoparticles Prevented Neointimal Hyperplasia and Reendothelialized Injured Artery

Controversies in Interventional Cardiology

Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Be Continued for More Than One Year and Preferably Indefinitely

Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Not Be Continued for More Than 1 Year and Preferably Indefinitely

Images and Case Reports in Interventional Cardiology

Apical Aortic Valve Implantation in a Patient With a Mechanical Valve Prosthesis in Mitral Position

Author Index

Volume 1, August–December, 2008

Spotlight